[Treatment of diabetic neuropathy].
Ziegler
D
D
Institut für Klinische Diabetologie, Deutsches Diabetes-Zentrum, Leibniz-Institut an der Heinrich-Heine-Universität Düsseldorf. dan.ziegler@ddz.uni-duesseldorf.de
Bierhaus
A
A
D000701:Analgesics, Opioid / Q000627:therapeutic use; D000818:Animals; D000927:Anticonvulsants / Q000627:therapeutic use; D000928:Antidepressive Agents / Q000627:therapeutic use; D000975:Antioxidants / Q000627:therapeutic use; D003921:Diabetes Mellitus, Experimental / Q000150:complications; D003929:Diabetic Neuropathies / Q000628:therapy*; D006801:Humans; D006943:Hyperglycemia / Q000150:complications / Q000378:metabolism; D009414:Nerve Growth Factors / Q000627:therapeutic use; D009437:Neuralgia / Q000209:etiology / Q000628:therapy*; D011115:Polyneuropathies / Q000628:therapy*; D047428:Protein Kinase Inhibitors / Q000627:therapeutic use; D011788:Quality of Life; D017382:Reactive Oxygen Species / Q000378:metabolism; D004561:Transcutaneous Electric Nerve Stimulation; D014665:Vasodilator Agents / Q000627:therapeutic use
D000701:Analgesics, Opioid; D000927:Anticonvulsants; D000928:Antidepressive Agents; D000975:Antioxidants; D009414:Nerve Growth Factors; D047428:Protein Kinase Inhibitors; D017382:Reactive Oxygen Species; D014665:Vasodilator Agents